Literature DB >> 22199371

Accelerated atherosclerosis in Apoe-/- mice heterozygous for the insulin receptor and the insulin receptor substrate-1.

Elena V Galkina1, Matthew Butcher, Susanna R Keller, Matthew Goff, Anthony Bruce, Hong Pei, Ian J Sarembock, John M Sanders, Melissa H Nagelin, Suseela Srinivasan, Rohit N Kulkarni, Catherine C Hedrick, Frank A Lattanzio, Anca D Dobrian, Jerry L Nadler, Klaus Ley.   

Abstract

OBJECTIVE: Prediabetic states are associated with accelerated atherosclerosis, but the availability of mouse models to study connections between these diseases has been limited. The aim of this study was to test the selective role of impaired insulin receptor/insulin receptor substrate-1 signaling on atherogenesis. METHODS AND
RESULTS: To address the effects of impaired insulin signaling associated with hyperinsulinemia on atherosclerosis in the absence of obesity and hyperglycemia, we generated insulin receptor (Insr)/insulin receptor substrate-1 (Insr1) double heterozygous apolipoprotein (Apoe)-knockout mice (Insr(+/-)Irs1(+/-)Apoe(-/-)) mice. Insr(+/-)Irs1(+/-)Apoe(-/-) mice fed a Western diet for 15 weeks showed elevated levels of fasting insulin compared to Insr(+/+)Irs1(+/+)Apoe(-/-) mice. There were no significant differences in glucose, triglyceride, HDL, VLDL, cholesterol levels or free fatty acid in the plasma of Insr(+/-)Irs1(+/-)Apoe(-/-) and Insr(+/+)Irs1(+/+)Apoe(-/-) mice. Atherosclerotic lesions were increased in male (brachiocephalic artery) and female (aortic tree) Insr(+/-)Irs1(+/-)Apoe(-/-) compared to Insr(+/+)Irs1(+/+)Apoe(-/-) mice. Bone marrow transfer experiments demonstrated that nonhematopoietic cells have to be Insr(+/-)Irs1(+/-) to accelerate atherosclerosis. Impaired insulin signaling resulted in decreased levels of vascular phospho-eNOS, attenuated endothelium-dependent vasorelaxation and elevated VCAM-1 expression in aortas of Insr(+/-)Irs1(+/-)Apoe(-/-) mice. In addition, phospho-ERK and vascular smooth muscle cell proliferation were significantly elevated in aortas of Insr(+/-)Irs1(+/-)Apoe(-/-) mice.
CONCLUSIONS: These results demonstrate that defective insulin signaling is involved in accelerated atherosclerosis in Insr(+/-)Irs1(+/-)Apoe(-/-) mice by promoting vascular dysfunction and inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22199371      PMCID: PMC3676303          DOI: 10.1161/ATVBAHA.111.240358

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  36 in total

1.  Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association.

Authors:  Scott M Grundy; Barbara Howard; Sidney Smith; Robert Eckel; Rita Redberg; Robert O Bonow
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

2.  Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin.

Authors:  K Kuboki; Z Y Jiang; N Takahara; S W Ha; M Igarashi; T Yamauchi; E P Feener; T P Herbert; C J Rhodes; G L King
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

3.  Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus.

Authors:  J M Olefsky; O G Kolterman; J A Scarlett
Journal:  Am J Physiol       Date:  1982-07

4.  Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways.

Authors:  Cecilia C Low Wang; Inga Gurevich; Boris Draznin
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

5.  Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting.

Authors:  R S Bar; P Gorden; J Roth; C R Kahn; P De Meyts
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

6.  Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice.

Authors:  Rohit N Kulkarni; Katrine Almind; H Joseph Goren; Jonathon N Winnay; Kohjiro Ueki; Terumasa Okada; C Ronald Kahn
Journal:  Diabetes       Date:  2003-06       Impact factor: 9.461

7.  Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.

Authors:  O G Kolterman; R S Gray; J Griffin; P Burstein; J Insel; J A Scarlett; J M Olefsky
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

Review 8.  Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators.

Authors:  Paul A VanderLaan; Catherine A Reardon; Godfrey S Getz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-11-06       Impact factor: 8.311

9.  Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus.

Authors:  Y Kawashima; J Chen; H Sun; D Lann; R J Hajjar; S Yakar; D Leroith
Journal:  Diabetologia       Date:  2009-05-13       Impact factor: 10.122

10.  Insulin binding, internalization, and insulin receptor regulation in fibroblasts from type II, non-insulin-dependent diabetic subjects.

Authors:  M J Prince; P Tsai; J M Olefsky
Journal:  Diabetes       Date:  1981-07       Impact factor: 9.461

View more
  18 in total

Review 1.  Animal models of atherosclerosis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

2.  Down-regulation of Insulin Receptor Substrate 1 during Hyperglycemia Induces Vascular Smooth Muscle Cell Dedifferentiation.

Authors:  Gang Xi; Christine Wai; Morris F White; David R Clemmons
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

Review 3.  Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease.

Authors:  Christian Rask-Madsen; C Ronald Kahn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

Review 4.  Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators.

Authors:  Jenny E Kanter; Karin E Bornfeldt
Journal:  Trends Endocrinol Metab       Date:  2012-11-13       Impact factor: 12.015

Review 5.  Vascular complications of diabetes: mechanisms of injury and protective factors.

Authors:  Christian Rask-Madsen; George L King
Journal:  Cell Metab       Date:  2013-01-08       Impact factor: 27.287

6.  Arterial insulin resistance in Yucatan micropigs with diet-induced obesity and metabolic syndrome.

Authors:  Cecilia C Low Wang; Li Lu; J Wayne Leitner; Mohammad Sarraf; Roberto Gianani; Boris Draznin; Clifford R Greyson; Jane E B Reusch; Gregory G Schwartz
Journal:  J Diabetes Complications       Date:  2013-04-02       Impact factor: 2.852

Review 7.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Authors:  Cecilia C Low Wang; Connie N Hess; William R Hiatt; Allison B Goldfine
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

Review 8.  Lipids and the endothelium: bidirectional interactions.

Authors:  Ira J Goldberg; Karin E Bornfeldt
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

9.  2013 Russell Ross memorial lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus-accelerated atherosclerosis.

Authors:  Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-04       Impact factor: 8.311

10.  Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts.

Authors:  Fabrice Bonnet; Ronan Roussel; Andrea Natali; Stéphane Cauchi; John Petrie; Martine Laville; Loïc Yengo; Philippe Froguel; Céline Lange; Olivier Lantieri; Michel Marre; Beverley Balkau; Ele Ferrannini
Journal:  Diabetologia       Date:  2013-08-14       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.